Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 220.

Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E., Cahalin, Paul, Clark, Richard E., Hills, Robert K. and Russell, Nigel H. 2018. Addition of the mammalian target of rapamycin inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial. Haematologica 103 (10) , pp. 1654-1661. 10.3324/haematol.2018.189514
file

Russell, Nigel, Burnett, Alan, Hills, Robert, Betteridge, Sophie, Dennis, Mike, Jovanovic, Jelena, Dillon, Richard and Grimwade, David 2018. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood 132 (13) , pp. 1452-1454. 10.1182/blood-2018-05-851824
Item availability restricted.
file

Marquis, Miriam, Beaubois, Cyrielle, Lavallée, Vincent-Philippe, Abrahamowicz, Michal, Danieli, Coraline, Lemieux, Sébastien, Ahmad, Imran, Wei, Andrew, Ting, Stephen B., Fleming, Shaun, Schwarer, Anthony, Grimwade, David, Grey, William, Hills, Robert K., Vyas, Paresh, Russell, Nigel, Sauvageau, Guy and Hébert, Josée 2018. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer Journal 8 (68) 10.1038/s41408-018-0103-6
file

Burnett, Alan K., Hills, R K, Nielsen, O J, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, Ian and Russell, N H 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32 , pp. 2693-2714. 10.1038/s41375-018-0148-3

Lucas, Claire M., Scott, Laura J., Carmell, Natasha, Holcroft, Alison K., Hills, Robert K., Burnett, Alan K. and Clark, Richard E. 2018. CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances 2 (9) , p. 964. 10.1182/bloodadvances.2017013615
file

Parkinson, Craig, Foley, Kieran, Whybra, Philip, Hills, Robert, Roberts, Ashley, Marshall, Christopher, Staffurth, John N. and Spezi, Emiliano 2018. Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods. EJNMMI Research 8 , 29. 10.1186/s13550-018-0379-3
file

Rajendram, Rathie, Taylor, Peter N, Wilson, Victoria J, Harris, Nicola, Morris, Olivia C, Tomlinson, Marjorie, Yarrow, Sue, Garrott, Helen, Herbert, Helen M, Dick, Andrew D, Cook, Anne, Gattamaneni, Rao, Jain, Rajni, Olver, Jane, Hurel, Steven J, Bremner, Fion, Drummond, Suzannah R, Kemp, Ewan, Ritchie, Diana M, Rumsey, Nichola, Morris, Daniel, Lane, Carol, Palaniappan, Nachi, Li, Chunhei, Pell, Julie, Hills, Robert, Ezra, Daniel G, Potts, Mike J, Jackson, Sue, Rose, Geoffrey E, Plowman, Nicholas, Bunce, Catey, Uddin, Jimmy M, Lee, Richard W J and Dayan, Colin M 2018. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology 6 (4) , pp. 299-309. 10.1016/S2213-8587(18)30021-4
file

Parkinson, C., Foley, K., Whybra, P., Hills, R., Roberts, A., Marshall, C., Staffurth, J. and Spezi, E. 2018. Dependency of patient risk stratification on PET target volume definition in Oesophageal cancer. Radiotherapy and Oncology 127 (Suppl) , S503-S504. 10.1016/S0167-8140(18)31241-6

Gale, Rosemary E., Popa, Teodora, Wright, Melissa, Khan, Naeem, Freeman, Sylvie D., Burnett, Alan K., Russell, Nigel H., Hills, Robert and Linch, David C. 2018. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood 131 (4) , pp. 468-471. 10.1182/blood-2017-08-802157
file

Foley, Kieran, Hills, Robert Kerrin, Berthon, Beatrice, Marshall, Christopher, Parkinson, Craig, Lewis, Wyn G, Crosby, Tom DL, Spezi, Emiliano and Roberts, Stuart A 2018. Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of pet in patients with oesophageal cancer. European Radiology 28 (1) , pp. 428-436. 10.1007/s00330-017-4973-y
file

Foley, Kieran G., Hills, Robert K., Berthon, Beatrice, Marshall, Christopher, Parkinson, Craig, Lewis, Wyn G., Crosby, Tom D. L., Spezi, Emiliano and Roberts, Stuart Ashley 2018. Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of PET in patients with oesophageal cancer. European Radiology 28 (1) , pp. 428-436. 10.1007/s00330-017-4973-y
file

Scurr, Martin, Pembroke, Thomas, Bloom, Anja, Roberts, David, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard, Brewster, Alison, Jones, Robert, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Wright, Melissa, Hills, Robert, Gallimore, Awen and Godkin, Andrew 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer A Randomized Clinical Trial. JAMA Oncology 3 (10) , e172579. 10.1001/jamaoncol.2017.2579
file

Scurr, Martin J, Pembroke, Tom, Bloom, Anja, Roberts, David J, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard A, Brewster, Alison E, Jones, Robert, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Hills, Robert, Gallimore, Awen and Godkin, Andrew 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research , clincanres.0895.2017. 10.1158/1078-0432.CCR-17-0895
file

Hyatt, Sam, Robinson, Rhiannon, Hepple, Nicole, Grimstead, Julia, Hills, Robert Kerrin, Fegan, Christopher, Jackson, Graham, allan, James, Pratt, Guy, Pepper, Christopher John and Baird, Duncan Martin 2017. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology 178 (1) , pp. 94-98. 10.1111/bjh.14643
file

Williams, Jenna, Heppel, Nicole, Britt-Compton, Bethan, Grimstead, Julia, Robinson, Rhiannon, Tauro, Sudhir, Bowen, David, Knapper, Steven, Groves, Michael, Hills, Robert, Pepper, Christopher J., Baird, Duncan M. and Fegan, Christopher D. 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology 178 (2) , pp. 240-249.
file

Rice, Cory, Shastrula, Prashanth Krishna, Kossenkov, Andrew V., Hills, Robert Kerrin, Baird, Duncan Martin, Showe, Louise C., Doukov, Tzanko, Janicki, Susan and Skordalakes, Emmanuel 2017. Structural and functional analysis of the human POT1-TPP1 telomeric complex. Nature Communications 8 , 14928. 10.1038/ncomms14928
file

Knapper, Steven, Russell, Nigel, Gilkes, Amanda, Hills, Robert K., Gale, Rosemary E., Cavenagh, James D., Jones, Gail, Kjeldsen, Lars, Grunwald, Michael R., Thomas, Ian, Konig, Heiko, Levis, Mark J. and Burnett, Alan K. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9) , pp. 1143-1154. 10.1182/blood-2016-07-730648
file

Hills, Robert Kerrin 2017. Non-inferiority trials: no better? no worse? no change? no pain? British Journal of Haematology 176 (6) , pp. 883-887. 10.1111/bjh.14504

Burnett, Alan Kenneth, Russell, N. H., Hills, Robert Kerrin, Kell, J., Nielsen, O. J., Dennis, M., Cahalin, P., Pocock, C., Ali, S., Burns, Sarah, Freeman, S., Milligan, D. and Clark, R. E. 2017. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 31 (2) , pp. 310-317. 10.1038/leu.2016.225

Hills, Robert Kerrin 2017. Statistical reporting in the BJH: some dos and don'ts. British Journal of Haematology 176 (3) , pp. 345-351. 10.1111/bjh.14426

Chilton, L, Harrison, C J, Ashworth, I, Murdy, D, Burnett, A K, Grimwade, D, Moorman, A V and Hills, R K 2017. Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia 31 (5) , pp. 1234-1237. 10.1038/leu.2017.37
file

Scurr, Martin, Pembroke, Thomas, Bloom, Anja, roberts, David, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Admas, Richard, Brewster, Alison, Jones, Robert, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Wright, Melissa, Hills, Robert, Gallimore, Awen and Godkin, Andrew 2017. MVA-5T4 immunotherapy (TroVax) and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): an open-label, randomized phase 1/2 clinical trial. JAMA Oncology
Item availability restricted.
file

Hills, Robert Kerrin 2016. Treatment intensification in diffuse large B-Cell lymphoma: lessons for clinical trial design. British Journal of Haematology 175 (4) , pp. 555-556. 10.1111/bjh.14400

Khan, N, Hills, Robert, Virgo, P, Couzens, S, Clark, N, Gilkes, Amanda, Richardson, P, Knapper, Steven, Grimwade, D, Russell, N H, Burnett, Alan and Freeman, S D 2016. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia 31 (5) , pp. 1059-1068. 10.1038/leu.2016.309
file

Khan, Naeem, Hills, Robert, Knapper, Steven, Steadman, Lora, Qureshi, Ushna, Rector, Jerrold L., Bradbury, Charlotte, Russell, Nigel H., Vyas, Paresh, Burnett, Alan K., Grimwade, David, Hole, Paul and Freeman, Sylvie D. 2016. Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCl2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia. PLOS ONE 11 (9) , e0163291. 10.1371/journal.pone.0163291
file

Chilton, L., Hills, Robert Kerrin, Burnett, A K and Harrison, C. J. 2016. The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities. Leukemia 30 (11) , pp. 2264-2267. 10.1038/leu.2016.200
file

Burnett, Alan K, Russell, Nigel H. and Hills, Robert Kerrin 2016. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 128 (3) , pp. 449-452. 10.1182/blood-2016-04-712091

Russell, N. H., Hills, Robert Kerrin, Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M. F., Cahalin, P., Dennis, M., Friis, L., Grech, A., Milligan, D., Clark, R. and Burnett, A. K. 2016. Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial. British Journal of Haematology 173 (S1) , p. 9.

Zabkiewicz, Joanna, Gilmour, Marie, Hills, Robert, Vyas, Pares, Bone, Elizabeth, Davidson, Alan, Burnett, Alan and Knapper, Steven 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7 (13) , pp. 16650-16662. 10.18632/oncotarget.7692
file

Ivey, Adam, Hills, Robert Kerrin, Simpson, Michael A., Jovanovic, Jelena V., Gilkes, Amanda F., Grech, Angela, Patel, Yashma, Bhudia, Neesa, Farah, Hassan, Mason, Joanne, Wall, Kerry, Akiki, Susanna, Griffiths, Michael, Solomon, Ellen, McCaughan, Frank, Linch, David C., Gale, Rosemary E., Vyas, Paresh, Freeman, Sylvie D., Russell, Nigel, Burnett, Alan K. and Grimwade, David 2016. Assessment of minimal residual disease in standard-risk AML. New England Journal of Medicine 374 (5) , pp. 422-433. 10.1056/NEJMoa1507471

Dickson, Glenda J., Bustraan, Sophia, Hills, Robert Kerrin, Ali, Akbar, Goldstone, Anthony H., Burnett, Alan, Linch, David C. and Gale, Rosemary E. 2016. The value of molecular stratification for CEBPA DM and NPM1 MUT FLT3 WT genotypes in older patients with acute myeloid leukaemia. British Journal of Haematology 172 (4) , pp. 573-580. 10.1111/bjh.13873

Burnett, Alan Kenneth, Cavenagh, J., Russell, N., Hills, Robert Kerrin, Kell, J., Jones, G., Nielsen, O. J., Khwaja, A., Thomas, Ian and Clark, R. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101 (6) , pp. 724-731. 10.3324/haematol.2016.141937
file

Munje, C., Hills, Robert Kerrin, Whetton, A., Burnett, A., Darley, Richard Lawrence and Tonks, Alex 2015. Cord blood-derived quiescent CD34+ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34+ cells. Gene Expression 16 (4) , pp. 169-175. 10.3727/105221615X14399878166159
file

Howard, Robert, McShane, Rupert, Lindesay, James, Ritchie, Craig, Baldwin, Ashley, Barber, Robert, Burns, Alistair, Dening, Tom, Findlay, David, Holmes, Clive, Jones, Robert, Jones, Roy, McKeith, Ian, Macharouthu, Ajay, O'Brien, John, Sheehan, Bart, Juszczak, Edmund, Katona, Cornelius, Hills, Robert Kerrin, Knapp, Martin, Ballard, Clive, Brown, Richard G, Banerjee, Sube, Adams, Jessica, Johnson, Tony, Bentham, Peter and Phillips, Patrick P J 2015. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology 14 (12) , pp. 1171-1181. 10.1016/S1474-4422(15)00258-6

Burnett, Alan K, Russell, Nigel H, Hills, Robert Kerrin, Bowen, David, Kell, Jonathan, Knapper, Steven, Morgan, Yvonne G, Lok, Jennie, Grech, Angela, Jones, Gail, Khwaja, Asim, Friis, Lone, McMullin, Mary Frances, Hunter, Ann, Clark, Richard E and Grimwade, David 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 16 (13) , pp. 1295-1305. 10.1016/S1470-2045(15)00193-X

Tawana, K., Wang, J., Renneville, A., Bodor, C., Hills, Robert, Loveday, C., Savic, A., Van Delft, F. W., Treleaven, J., Georgiades, P., Uglow, E., Asou, N., Uike, N., Debeljak, M., Jazbec, J., Ancliff, P., Gale, R., Thomas, X., Mialou, V., Dohner, K., Bullinger, L., Mueller, B., Pabst, T., Stelljes, M., Schlegelberger, B., Wozniak, E., Iqbal, S., Okosun, J., Araf, S., Frank, A.-K., Lauridsen, F. B., Porse, B., Nerlov, C., Owen, C., Dokal, I., Gribben, J., Smith, M., Preudhomme, C., Chelala, C., Cavenagh, J. and Fitzgibbon, J. 2015. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 126 (10) , pp. 1214-1223. 10.1182/blood-2015-05-647172

Khan, Naeem, Freeman, Sylvie D., Virgo, Paul, Couzens, Steve, Richardson, Peter, Thomas, Ian, Grech, Angela, Vyas, Paresh, Grimwade, David, Russell, Nigel H., Burnett, Alan K. and Hills, Robert Kerrin 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170 (1) , pp. 80-84. 10.1111/bjh.13398

Russell, N H, Kjeldsen, L, Craddock, C, Pagliuca, A, Yin, J A, Clark, R E, Howman, A, Hills, Robert Kerrin and Burnett, A K 2015. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia 29 (7) , pp. 1478-1484. 10.1038/leu.2014.319

Gale, R. E., Lamb, K., Allen, C., El-Sharkawi, D., Stowe, C., Jenkinson, S., Tinsley, S., Dickson, G., Burnett, Alan K, Hills, Robert Kerrin and Linch, D. C. 2015. Simpson's Paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. Journal of Clinical Oncology 33 (18) , pp. 2072-2083. 10.1200/JCO.2014.59.2022

Simpson, Katherine, Jones, R. E., Grimstead, Julia W., Hills, Robert Kerrin, Pepper, Christopher John and Baird, Duncan Martin 2015. Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients. Molecular Oncology 9 (6) , pp. 1186-1193. 10.1016/j.molonc.2015.02.003
file

Lazenby, Michelle, Hills, Robert Kerrin, Burnett, Alan Kenneth and Zabkiewicz, Joanna 2015. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39 (6) , pp. 617-624. 10.1016/j.leukres.2015.03.016
file

Dennis, M., Russell, N., Hills, Robert Kerrin, Hemmaway, C., Panoskaltsis, N., McMullin, M. F., Kjeldsen, L., Dignum, H., Thomas, Ian, Clark, R. E., Milligan, D. and Burnett, Alan 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125 (19) , pp. 2923-2932. 10.1182/blood-2014-10-608117

Kuhnl, A., Valk, P. J. M., Sanders, M. A., Ivey, A., Hills, Robert Kerrin, Mills, K. I., Gale, R. E., Kaiser, M. F., Dillon, R., Joannides, M., Gilkes, Amanda F., Haferlach, T., Schnittger, S., Duprez, E., Linch, D. C., Delwel, R., Lowenberg, B., Baldus, C. D., Solomon, E., Burnett, Alan K. and Grimwade, D. 2015. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood 125 (19) , pp. 2985-2994. 10.1182/blood-2014-12-613703

Burnett, A. K., Russell, N. H., Hills, Robert Kerrin, Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M.-F., Cahalin, P., Dennis, M., Friis, L., Thomas, Ian, Milligan, D. and Clark, R. E. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125 (25) , pp. 3878-3885. 10.1182/blood-2015-01-623447

Scurr, Martin John, Brown, Clare M., Costa Bento, Diana Filipa, Betts, G., Rees, B. I., Hills, Robert Kerrin, Gallimore, Awen Myfanwy and Godkin, Andrew James 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI Journal of the National Cancer Institute 107 (4) , djv001. 10.1093/jnci/djv001
file

Walter, R B, Othus, M, Burnett, A K, Löwenberg, B, Kantarjian, H M, Ossenkoppele, G J, Hills, Robert Kerrin, Ravandi, F, Pabst, T, Evans, Anna, Pierce, S R, Vekemans, M-C, Appelbaum, F R and Estey, E H 2015. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29 (2) , pp. 312-320. 10.1038/leu.2014.242

Lin, Thet Thet, Norris, Kevin, Heppel, Nicole H., Pratt, Guy, Allan, James M., Allsup, David J., Bailey, James, Cawkwell, Lynn, Hills, Robert, Grimstead, Julia W., Jones, Rhiannon E., Britt-Compton, Bethan, Fegan, Christopher, Baird, Duncan Matrin and Pepper, Christopher 2014. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology 167 (2) , pp. 214-223. 10.1111/bjh.13023

Hills, Robert Kerrin, Castaigne, Sylvie, Appelbaum, Frederick R., Delaunay, Jacques, Petersdorf, Stephen, Othus, Megan, Estey, Elihu H, Dombret, Hervé, Chevret, Sylvie, Ifrah, Norbert, Cahn, Jean-Yves, Récher, Christian, Chilton, Lucy, Moorman, Anthony V. and Burnett, Alan K. 2014. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncology 15 (9) , pp. 986-996. 10.1016/S1470-2045(14)70281-5

Linch, David C., Hills, Robert, Burnett, Alan K., Khwaja, Asim and Gale, Rosemary E. 2014. Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 124 (2) , pp. 273-276. 10.1182/blood-2014-02-554667

Roboz, Gail J., Rosenblat, Todd, Arellano, Martha, Gobbi, Marco, Altman, Jessica K., Montesinos, Pau, O'Connell, Casey, Solomon, Scott R., Pigneux, Arnaud, Vey, Norbert, Hills, Robert Kerrin, Jacobsen, Tove Flem, Gianella-Borradori, Athos, Foss, Oivind, Vetrhusand, Sylvia and Giles, Francis J. 2014. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology 32 (18) , pp. 1919-1926. 10.1200/JCO.2013.52.8562

Zabkiewicz, Joanna, Pearn, Lorna, Hills, Robert, Morgan, Rhys G., Tonks, Alex, Burnett, Alan K. and Darley, Richard 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99 (5) , pp. 858-864. 10.3324/haematol.2013.096487

Mohamed, Imran, Hills, Robert and Burnett, Alan K. 2014. Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials. British Journal of Haematology 165 (1) , pp. 147-151. 10.1111/bjh.12705

Grimwade, David, Jovanovic, Jelena V. and Hills, Robert 2014. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia? Best Practice & Research Clinical Haematology 27 (1) , pp. 53-61. 10.1016/j.beha.2014.04.002

Lazenby, Michelle, Gilkes, Amanda, Marrin, C., Evans, Anna, Hills, Robert Kerrin and Burnett, A. K. 2014. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28 , pp. 1953-1959. 10.1038/leu.2014.90

El-Sharkawi, Dima, Ali, Akbar, Evans, Catherine M., Hills, Robert, Burnett, Alan K., Linch, David C. and Gale, Rosemary E. 2014. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. Leukemia and Lymphoma 55 (6) , pp. 1326-1331. 10.3109/10428194.2013.833332

Chilton, L., Hills, Robert Kerrin, Harrison, C. J., Burnett, A. K., Grimwade, D. and Moorman, A. V. 2014. Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. Leukemia 28 , pp. 321-328. 10.1038/leu.2013.198

Hole, Paul Spencer, Zabkiewicz, Joanna, Munje, Chinmay, Newton, Zarabeth, Pearn, Lorna, White, Paul Charles, Marquez, Nuria, Hills, Robert Kerrin, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122 (19) , pp. 3322-3330. 10.1182/blood-2013-04-491944

Allen, C., Hills, Robert Kerrin, Lamb, K., Evans, C., Tinsley, S., Sellar, R., O'Brien, M., Yin, J. L., Burnett, A. K., Linch, D. C. and Gale, R. E. 2013. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 27 (9) , pp. 1891-1901. 10.1038/leu.2013.186

Burnett, Alan Kenneth, Russell, Nigel H., Hills, Robert Kerrin, Hunter, Ann E., Kjeldsen, Lars, Yin, John Yin., Gibson, Brenda E. S., Wheatley, Keith and Milligan, Donald 2013. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. Journal of Clinical Oncology 31 (27) , pp. 3360-3368. 10.1200/JCO.2012.47.4874

Burnett, Alan Kenneth, Russell, N. H., Hunter, A. E., Milligan, D., Knapper, Steven, Wheatley, K., Yin, J., McMullin, M. F., Ali, S., Bowen, D. and Hills, Robert Kerrin 2013. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122 (8) , pp. 1384-1394. 10.1182/blood-2013-04-496596

Senapati, A., Gray, R. G., Middleton, L. J., Harding, J., Hills, Robert Kerrin, Armitage, N. C. M., Buckley, L. and Northover, J. M. A. 2013. PROSPER: a randomised comparison of surgical treatments for rectal prolapse. Colorectal Disease 15 (7) , pp. 858-868. 10.1111/codi.12177

Green, Claire L., Tawana, Kiran, Hills, Robert Kerrin, Bodor, Csaba, Fitzgibbon, Jude, Inglott, Sarah, Ancliff, Phil, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2013. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. British Journal of Haematology 161 (5) , pp. 701-705. 10.1111/bjh.12317

Pembroke, Thomas, Christian, Adam, Jones, Emma, Hills, Robert Kerrin, Wang, Edward Chung Yern, Gallimore, Awen Myfanwy and Godkin, Andrew James 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a 10.1136/gutjnl-2013-304472
file

Burnett, Alan Kenneth and Hills, Robert Kerrin 2013. No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard Medical Research Council induction chemotherapy - Reply [Letter]. Journal of Clinical Oncology 31 (13) , pp. 1700-1701. 10.1200/JCO.2013.48.6571

Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D., Ivey, A., Virgo, P., Hills, Robert Kerrin, McSkeane, T., Arrazi, J., Knapper, Steven, Brookes, C., Davies, B., Price, A., Wall, K., Griffiths, M., Cavenagh, J., Majeti, R., Weissman, I., Burnett, Alan Kenneth and Vyas, P. 2013. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27 (5) , pp. 1028-1036. 10.1038/leu.2012.312

Nacheva, Ellie P., Grace, Colin D., Brazma, Diana, Gancheva, Katya, Howard-Reeves, Julie, Rai, Lena, Gale, Rosemary E., Linch, David C., Hills, Robert Kerrin, Russell, Nigel, Burnett, Alan Kenneth and Kottaridis, Panagiotis D. 2013. Does BCR/ABL1 positive acute myeloid leukaemia exist? British Journal of Haematology 161 (4) , pp. 541-550. 10.1111/bjh.12301

Burnett, Alan Kenneth, Goldstone, Anthony, Hills, Robert Kerrin, Milligan, Donald, Prentice, Archie, Yin, John, Wheatley, Keith, Hunter, Ann and Russell, Nigel 2013. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. Journal of Clinical Oncology 31 (10) , pp. 1293-1301. 10.1200/JCO.2011.40.5977

Burnett, Alan Kenneth, Hills, Robert Kerrin, Grimwade, D., Jovanovic, J. V., Craig, J., McMullin, M. F., Kell, J., Wheatley, K., Yin, J. A. L., Hunter, A., Milligan, D and Russell, N. H. 2013. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 27 (4) , pp. 843-851. 10.1038/leu.2012.360

Ling, Victoria, Burnett, Alan Kenneth, Bradstock, Ken, Seymour, John F., Hills, Robert Kerrin and Wei, Andrew 2013. Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. British Journal of Haematology 160 (6) , pp. 861-863. 10.1111/bjh.12178

McLornan, Donal, Hay, Jodie, McLaughlin, Kirsty, Holohan, Caitriona, Burnett, Alan Kenneth, Hills, Robert Kerrin, Johnston, Patrick G., Mills, Ken Ian, McMullin, Mary Frances and Longley, Daniel B. 2013. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. British Journal of Haematology 160 (2) , pp. 188-198. 10.1111/bjh.12108

Walter, R. B., Othus, M., Burnett, Alan K., Lowenberg, B., Kantarjian, H. M., Ossenkoppele, G. J., Hills, Robert Kerrin, van Montfort, K. G. M., Ravandi, F., Evans, Anna, Pierce, S. R., Appelbaum, F. R. and Estey, E. H. 2013. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 121 (13) , p. 2424. 10.1182/blood-2012-10-462440

Burnett, Alan Kenneth, Hills, Robert Kerrin, Hunter, A. E., Milligan, D., Kell, W. J., Wheatley, K., Yin, J., McMullin, M. F., Dignum, H., Bowen, Derrick John and Russell, Nicholas H. 2013. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 27 , pp. 75-81. 10.1038/leu.2012.229

Daud, Siti Sarah, Pumford, Sara L, Gilmour, Marie N., Gilkes, Amanda F., Burnett, Alan Kenneth, Hills, Robert Kerrin, Tonks, Alex and Darley, Richard Lawrence 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120 (21) , 1281.

Bradbury, Charlotte Ann, Ward, Janice, Vyas, Paresh, Russell, Higel H., Grimwade, David, Hills, Robert Kerrin, Burnett, Alan Kenneth, Craddock, Charles F. and Freeman, Sylvie 2012. Residual disease detection by flow cytometry predicts risk of relapse and overall survival in patients with Acute Myeloid Leukemia following reduced intensity- and Myeloablative- Allogeneic Hematopoietic Cell Transplantation [Abstract]. Blood -New York- 120 (21)

Russell, Nigel H., Hills, Robert Kerrin, Kjeldsen, Lars, Yin, John L., Craddock, Charles and Burnett, Alan Kenneth 2012. Reduced intensity transplant may improve survival in patients over the age of 40, especially if a sibling donor Is Used: pooled analysis of 2454 patients and 407 transplants in the UK NCRI AML15 and AML16 trials [Abstract]. Blood -New York- 120 (21)

Burnett, Alan Kenneth, Russell, Nigel H., McMullin, Mary Frances, Kell, Jonathan, Ali, Sahra, Moreton, Paul, Wei, Andrew H., Kjeldsen, Lars and Hills, Robert Kerrin 2012. A randomised comparison of Clofarabine versus low dose Ara-C as first line treatment for older patients with AML [Abstract]. Blood -New York- 120 (21)

Burnett, Alan Kenneth, Russell, Nigel H., Kell, Jonathan, Kjeldsen, Lars, Milligan, Donald, Cahalin, Paul and Hills, Robert Kerrin 2012. A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial [Abstract]. Blood -New York- 120 (21)

Yin, John A. Liu, O'Brien, Michelle A., Hills, Robert Kerrin, Daly, Sarah B., Wheatley, Keith and Burnett, Alan Kenneth 2012. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120 (14) , pp. 2826-2835. 10.1182/blood-2012-06-435669

Burnett, Alan Kenneth, Russell, Nigel H., Hills, Robert Kerrin, Kell, Jonathan, Freeman, Sylvie, Kjeldsen, Lars, Hunter, Ann E., Yin, John, Craddock, Charles F., Dufva, Inge Hoegh, Wheatley, Keith and Milligan, Donald 2012. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of Clinical Oncology 30 (32) , pp. 3924-3931. 10.1200/JCO.2012.42.2964

Coles, Steven, Hills, Robert Kerrin, Wang, Edward Chung Yern, Burnett, Alan Kenneth, Man, Stephen Tzekwung, Darley, Richard Lawrence and Tonks, Alex 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9) , pp. 2148-2151. 10.1038/leu.2012.77
file

Hills, Robert Kerrin 2012. The contribution of randomized trials to the cure of haematological disorders from Bradford Hill onwards. British Journal of Haematology 158 (6) , pp. 691-699. 10.1111/j.1365-2141.2012.09213.x

Coles, Steven, Hills, Robert Kerrin, Wang, Edward Chung Yern, Burnett, Alan Kenneth, Man, Stephen Tzekwung, Darley, Richard Lawrence and Tonks, Alex 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9) , pp. 2146-2148. 10.1038/leu.2012.75
file

Burnett, Alan Kenneth, Russell, Nigel H., Culligan, Dominic, Cavanagh, Jamie, Kell, Jonathan, Wheatley, Keith, Virchis, Andra, Hills, Robert Kerrin and Milligan, Donald 2012. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. British Journal of Haematology 158 (4) , pp. 519-522. 10.1111/j.1365-2141.2012.09165.x

Burnett, Alan Kenneth, Freeman, S., Hills, Robert Kerrin, Hunter, A. E., Milligan, D. W., Kell, W. J., Wheatley, K., Yin, J. A. L., Ali, S., Kjeldsen, L., Goldstone, A. H., Bowen, D and Russell, N. H. 2012. The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience [Abstract]. British Journal of Haematology 157 (S1) , p. 1. 10.1111/j.1365-2141.2012.09071.x

El-Sharkawi, D., Ali, A., Evans, C. M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2012. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukaemia [Abstract]. British Journal of Haematology 157 (S1) , p. 56. 10.1111/j.1365-2141.2012.09071.x

Allen, C. G., Tinsley, S. P., Hills, Robert Kerrin, Evans, C. M., Lamb, K., Sellar, R. S., Sale, M., Yin, J. L., Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2012. The impact of mutant level on clinical outcome in acute myeloid leukaemia differs according to the mutated gene [Abstract]. British Journal of Haematology 157 (S1) , p. 20. 10.1111/j.1365-2141.2012.09071.x

Sunter, Nicola J., Scott, Kathryn, Hills, Robert Kerrin, Grimwade, David, Taylor, Sheila, Worrillow, Lisa J., Fordham, Sarah E., Forster, Victoria J., Jackson, Graham, Bomken, Simon, Jones, Gail and Allan, James M. 2012. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 119 (1) , pp. 196-205. 10.1182/blood-2011-04-349803

Pepper, Christopher John, Majid, Aneela, Lin, Thet Thet, Hewamana, Saman, Pratt, Guy, Walewska, Renata, Gesk, Stefan, Siebert, Reiner, Wagner, Simon, Kennedy, Ben, Miall, Fiona, Davis, Zadie A., Tracy, Ian, Gardiner, Anne C., Brennan, Paul, Hills, Robert Kerrin, Dyer, Martin J. S., Oscier, David and Fegan, Christopher Daniel 2012. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British Journal of Haematology 156 (4) , pp. 499-507. 10.1111/j.1365-2141.2011.08974.x

Sunter, Nicola J., Scott, Kathryn, Hills, Robert Kerrin, Grimwade, David, Taylor, Sheila, Worrillow, Lisa J., Fordham, Sarah E., Forster, Victoria J., Jackson, Graham, Bomken, Simon, Jones, Gail and Allan, James M. 2012. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 119 (1) , pp. 196-205. 10.1182/blood-2011-04-349803

Howard, Robert, McShane, Rupert, Lindesay, James, Ritchie, Craig, Baldwin, Ashley, Barber, Robert, Burns, Alistair, Dening, Tom, Findlay, David, Holmes, Clive, Hughes, Alan, Jacoby, Robin, Jones, Rob, Jones, Roy, McKeith, Ian, Macharouthu, Ajay, O'Brien, John, Passmore, Peter, Sheehan, Bart, Juszczak, Edmund, Katona, Cornelius, Hills, Robert Kerrin, Knapp, Martin, Ballard, Clive, Brown, Richard, Banerjee, Sube, Onions, Caroline, Griffin, Mary, Adams, Jessica, Gray, Richard, Johnson, Tony, Bentham, Peter and Phillips, Patrick 2012. Donepezil and memantine for moderate-to-severe Alzheimer's Disease. New England Journal of Medicine 366 (10) , pp. 893-903. 10.1056/NEJMoa1106668

Coles, Steven, Man, Stephen Tzekwung, Hills, Robert Kerrin, Wang, Edward Chyng Yern, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1) , p. 178. 10.1111/j.1365-2567.2011.03534.x

Craddock, Charles F., Goardon, Nicolas, Quek, Lynn, Freeman, Sylvie, Siddique, Shamyla, Raghavan, Manoj, Schuh, Anna, Grimwade, David, Hills, Robert Kerrin, Brookes, Cassandra, Griffiths, Michael, Cavenagh, James D., Majeti, Ravindra, Weissman, Irving L., Burnett, Alan Kenneth and Vyas, Paresh 2011. Quantitation of leukemic stem cell populations predicts clinical outcome in Acute Myeloid Leukaemia. Blood -New York- 118 (21) , p. 292.

Burnett, Alan Kenneth, Hills, Robert Kerrin, Hunter, Ann E., Milligan, Donald, Kell, William J., Wheatley, Keith, Yin, John L., Ali, Sahra, Kjeldsen, Lars, Bowen, David and Russell, Nigel H. 2011. The addition of Gemtuzumab Ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood -New York- 118 (21) , p. 268.

Allen, C. G., Hills, Robert Kerrin, Evans, C. M., Lamb, K., Sellar, R., Moorman, A. V., Sale, M., Liu-Yin, J. A., Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2011. Mutations in a large cohort of young adult patients with core binding factor acute myeloid leukemia: Impact on outcome and the selection of patients for alternative treatment including transplantation in first complete remission [Abstract]. Blood 118 (21) , p. 193.

Knapper, Steven, White, Paul Charles, Levis, Mark J., Hills, Robert Kerrin, Russell, Nigel H. and Burnett, Alan Kenneth 2011. The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials. Blood -New York- 118 (21) , p. 194.

Mohamedali, Azim M., Hills, Robert Kerrin, Nasser, Erick E., Abdallah, Atiyeh, Shinde, Sneha, Kulasekararaj, Austin G., Gilkes, Amanda F., Lea, Nicholas, Burnett, Alan Kenneth and Mufti, Ghulam J. 2011. Single Nucleotide Polymorphism Array (SNP-A) karyotype is the best predictor of prognosis in normal cytogenetics Acute Myeloid Leukaemia (AML). Blood -New York- 118 (21) , pp. 188-189.

Hills, Robert Kerrin and Burnett, Alan Kenneth 2011. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. Blood 118 (9) , pp. 2389-2394. 10.1182/blood-2011-02-337261

Pallis, M, Hills, Robert Kerrin, White, Paul Charles, Grundy, M, Russell, N and Burnett, Alan Kenneth 2011. Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. Blood Cancer Journal 1 , e23.

Dojcinov, Stefan D., Venkataraman, G., Pittaluga, S., Wlodarska, I., Schrager, J. A., Raffeld, M., Hills, Robert Kerrin and Jaffe, E. .S 2011. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 117 (18) , pp. 4726-4735. 10.1182/blood-2010-12-323238

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald, Kjeldsen, Lars, Kell, Jonathan, Russell, Nigel H., Yin, John A. L., Hunter, Ann, Goldstone, Anthony H. and Wheatley, Keith 2011. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 Trial. Journal of Clinical Oncology 29 (4) , pp. 369-377. 10.1200/JCO.2010.31.4310

Coles, Steven, Wang, Edward Chung Yern, Man, Stephen Tzekwung, Hills, Robert Kerrin, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5) , pp. 792-799. 10.1038/leu.2011.1

Daniels, J. P., Gray, J., Pattison, H. M., Gray, R., Hills, Robert Kerrin and Khan, K. S. 2011. Intrapartum tests for group B streptococcus: accuracy and acceptability of screening. BJOG: An International Journal of Obstetrics & Gynaecology 118 (2) , pp. 257-265. 10.1111/j.1471-0528.2010.02725.x

Daniels, J. P., Gray, J., Pattison, H. M., Gray, R., Hills, Robert Kerrin and Khan, K. S. 2011. Intrapartum tests for group B streptococcus: accuracy and acceptability of screening. BJOG-an International Journal of Obstetrics and Gynaecology 118 (2) , pp. 257-265. 10.1111/j.1471-0528.2010.02725.x

Smith, Matthew L., Hills, Robert Kerrin and Grimwade, David 2011. Independent prognostic variables in acute myeloid leukaemia. Blood Reviews 25 (1) , pp. 39-51. 10.1016/j.blre.2010.10.002

Burnett, Alan Kenneth and Hills, Robert Kerrin 2011. Who should be transplanted in first remission of Acute Myeloid Leukaemia? Current Treatment Options in Oncology 12 (4) , pp. 329-340. 10.1007/s11864-011-0169-x

Smith, Matthew L., Hills, Robert Kerrin and Grimwade, David 2011. Independent prognostic variables in acute myeloid leukaemia. Blood Reviews 25 (1) , pp. 39-51. 10.1016/j.blre.2010.10.002

Majid, Aneela, Lin, Thet Thet, Best, Giles, Fishlock, Keith, Hewamana, Saman, Pratt, Guy, Yallop, Deborah, Buggins, Andrea G. S., Wagner, Simon, Kennedy, Ben J., Miall, Fiona, Hills, Robert Kerrin, Devereux, Stephen, Oscier, David G., Dyer, Martin J. S., Fegan, Christopher Daniel and Pepper, Christopher John 2011. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leukemia Research 35 (6) , pp. 750-756. 10.1016/j.leukres.2010.10.022

Burnett, Alan Kenneth, Hills, Robert Kerrin, Hunter, A., Milligan, D., Kell, Jonathan, Wheatley, K., Yin, J., McMullin, M. F., Cahalin, P., Craig, J., Bowen, D. and Russell, N. 2011. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25 (7) , pp. 1122-1127. 10.1038/leu.2011.59

Green, Claire, Evans, Catherine M., Zhao, Lu, Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2011. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118 (2) , pp. 409-412. 10.1182/blood-2010-12-322479

Dojcinov, Stefan D., Venkataraman, Girish, Pittaluga, Stefania, Wlodarska, Iwona, Schrager, Jeffrey A., Raffeld, Mark, Hills, Robert Kerrin and Jaffe, Elaine S. 2011. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 117 (18) , pp. 4726-4735. 10.1182/blood-2010-12-323238

Bajuaifer, N., Grundy, M., Hills, Robert Kerrin, Russell, N. H., Pallis, M. and Seedhouse, C. 2010. A polymorphism in the 3'UTR region of ABCB1 is associated with increased allele activity with corresponding increases in P-glycoprotein expression and function [Abstract]. Blood 116 (21) , p. 1626.

Wei, A. H., Sadawarte, S., Catalano, J., Hills, Robert Kerrin, Avery, S., Patil, S. S., Burnett, Alan Kenneth and Spencer, A. 2010. A phase Ib study Combining the mTOR inhibitor everolimus (RAD001) with low-dose cytarabine In untreated elderly AML [Abstract]. Blood 116 (21) , pp. 1351-1352.

Mohamedali, A., Hills, Robert Kerrin, Nasser, E. E., Abdallah, A., Kulasekararaj, A. G., Gilkes, Amanda F., Lea, N., Burnett, Alan Kenneth and Mufti, G. J. 2010. Prognostic significance of cryptic genomic aberrations in AML with normal karyotype [Abstract]. Blood 116 (21) , p. 1125.

Pallis, M., White, Paul Charles, Hills, Robert Kerrin, Grundy, M., Russell, N. H. and Burnett, Alan Kenneth 2010. Analysis of the interaction of induction regimens with P-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 Trial [Abstract]. Blood 116 (21) , p. 1123.

Sunter, Nicola J., Scott, Kathryn, Hills, Robert Kerrin, Grimwade, David, Taylor, Sheila, Worrillow, Lisa, Jackson, Graham, Bomken, Simon, Jones, Gail and Allan, James M. 2010. A functional polymorphism in the CD95 cell death receptor associated with prognosis in acute promyelocytic leukemia [Abstract]. Blood 116 (21) , 756.

Freeman, S., Hills, Robert Kerrin, Virgo, P., Couzens, Stephen, Lowdell, M. W., McNamara, C. J., White, Paul Charles and Burnett, Alan Kenneth 2010. Detection of immunophenotypic residual disease after induction therapy is an independent prognostic factor for duration of remission in older AML patients treated intensively [Abstract]. Blood 116 (21) , pp. 1118-1119.

Zabkiewicz, Joanna, Pearn, Lorna, Hills, Robert Kerrin, Morgan, Rhys G., Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116 (21) , pp. 892-893.

Morgan, Rhys Gareth, Pearn, Lorna, Liddiard, Kate, Hills, Robert Kerrin, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116 (21) , 1573.

Daniels, J. P., Middleton, L., Xiong, T., Champaneria, R., Johnson, N. P., Lichten, E. M., Sutton, C., Vercellini, P., Gray, R., Hills, Robert Kerrin, Jones, K. D., Aimi, G. and Khan, K. S. 2010. Individual patient data meta-analysis of randomized evidence to assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic pain. Human Reproduction Update 16 (6) , pp. 568-576. 10.1093/humupd/dmq031

Stringaris, K., Barrett, A. J., Hills, Robert Kerrin, Linch, D. C., Gale, R., Allen, C., Garland, P., Sargent, R., de Lavallade, H., Alsuliman, A., Khoder, A., Gabriel, I. H., Sekine, T., Burnett, Alan Kenneth, Rezvani, K. and Apperley, J. F. 2010. A distinct signature of natural killer cell KIR gene frequencies in secondary AML compared with de novo AML and normal controls. Blood 116 (21) , pp. 711-712.

Coles, Steven, Man, Stephen Tzekwung, Hills, Robert Kerrin, Wang, Edward Chung Yern, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21) , p. 218.

Green, C. L., Evans, C. M., Hills, Robert Kerrin, Zhao, L., Burnett, Alan Kenneth, Linch, D. C. and Gale, R. 2010. Younger adult acute myeloid leukemia (AML) patients with IDH2-R140 mutations have a significantly better prognosis than those with either IDH2-R172 or IDH1 mutations [Abstract]. Blood 116 (21) , p. 50.

Green, Claire L., Evans, Catherine M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116 (15) , pp. 2779-2782. 10.1182/blood-2010-02-270926

Grimwade, David, Hills, Robert Kerrin, Moorman, Anthony V., Walker, Helen, Chatters, Stephen, Goldstone, Anthony H., Wheatley, Keith, Harrison, Christine J. and Burnett, Alan Kenneth 2010. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116 (3) , pp. 354-365. 10.1182/blood-2009-11-254441

Grimwade, D., Hills, Robert Kerrin, Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J. and Burnett, Alan Kenneth 2010. Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials [Abstract]. British Journal of Haematology 149 (S1) , p. 17. 10.1111/j.1365-2141.2010.08116.x

Liddiard, Kate, Hills, Robert Kerrin, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29 (13) , pp. 2005-2012. 10.1038/onc.2009.462

Bick, Debra E., Kettle, Christine, Macdonald, Sue, Thomas, Peter W., Hills, Robert Kerrin and Ismail, Khaled MK 2010. PErineal Assessment and Repair Longitudinal Study (PEARLS): protocol for a matched pair cluster trial. BMC Pregnancy and Childbirth 10 , 10.
file

Burnett, Alan Kenneth, Hills, Robert Kerrin, Green, C., Jenkinson, S., Koo, K., Patel, Y., Guy, Carol, Gilkes, Amanda F., Milligan, D.W., Goldstone, A.H., Prentice, A.G., Wheatley, K., Linch, D. C. and Gale, R. E. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115 (5) , pp. 948-956. 10.1182/blood-2009-08-236588

Grimwade, David, Jovanovic, Jelena V., Hills, Robert Kerrin, Solomon, Ellen, Lo-Coco, Francesco, Wheatley, Keith and Burnett, Alan Kenneth 2010. How should we prevent hematologic relapse of acute promyelocytic leukemia? Reply [Letter]. Journal of Clinical Oncology 28 (4) , E63-E64. 10.1200/JCO.2009.24.9995

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald W., Goldstone, Anthony H., Prentice, Archibald G., McMullin, Mary-Frances, Duncombe, Andrew, Gibson, Brenda and Wheatley, Keith 2010. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology 28 (4) , pp. 586-595. 10.1200/JCO.2009.22.9088

Green, C. L., Evans, C. M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukaemia is dependent on FLT3/ITD status [Abstract]. British Journal of Haematology 149 (S1) , p. 17. 10.1111/j.1365-2141.2010.08116.x

Daniels, J. P., Middleton, L., Xiong, T., Champaneria, R., Johnson, N. P., Lichten, E. M., Sutton, C., Vercellini, P., Gray, R., Hills, Robert Kerrin, Jones, K. D., Aimi, G. and Khan, K. S. 2010. Individual patient data meta-analysis of randomized evidence to assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic pain. Human Reproduction Update 16 (6) , pp. 568-576. 10.1093/humupd/dmq031

Burnett, Alan Kenneth, Hills, Robert Kerrin, Green, Claire, Jenkinson, Sarah, Koo, Kenneth, Patel, Yashma, Guy, Carol, Gilkes, Amanda F., Milligan, Donald W., Goldstone, Anthony. H., Prentice, Archibald G., Wheatley, Keith, Linch, David C. and Gale, Rosemary E. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115 (5) , pp. 948-956. 10.1182/blood-2009-08-236588

Green, Claire L., Evans, Catherine M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116 (15) , pp. 2779-2782. 10.1182/blood-2010-02-270926

Harrison, Chirstine J., Hills, Robert Kerrin, Moorman, Anthony V., Grimwade, David J., Hann, Ian, Webb, David K. H., Wheatley, Keith, de Graaf, Siebold S. N., van den Berg, Eva, Burnett, Alan Kenneth and Gibson, Brenda E. S. 2010. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. Journal of Clinical Oncology 28 (16) , pp. 2674-2681. 10.1200/JCO.2009.24.8997

Green, Claire, Koo, K. K., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2010. Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations. Journal of Clinical Oncology 28 (16) , pp. 2739-2747. 10.1200/JCO.2009.26.2501

Cilloni, Daniel, Renneville, Aline, Hermitte, Fabienne, Hills, Robert Kerrin, Daly, Sarah, Jovanovic, Jelena V., Gottardi, Enrico, Fava, Milena, Schnittger, Susanne, Weiss, Tamara, Izzo, Barbara, Nomdedeu, Josep, van der Heijden, Adrian, van der Reijden, Bert A., Jansen, Joop H., van der Velden, Vincent H. J., Ommen, Hans, Preudhomme, Claude, Saglio, Giuseppe and Grimwade, David 2009. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Journal of Clinical Oncology 27 (31) , pp. 5195-5201. 10.1200/JCO.2009.22.4865

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald, Hunter, Ann E., Goldstone, Anthony H., Prentice, Archie G., Gibson, Brenda E. S., Kjeldsen, Lars, Yin, John A. L., Wheatley, Keith and Russell, Nigel H. 2009. Attempts to optimise induction and consolidation chemotherapy in patients with Acute Myeloid Leukaemia: results of the MRC AML15 trial. Blood -New York- 114 (22) , p. 200.

Knapper, Steven, Burnett, Alan Kenneth, Hills, Robert Kerrin, Small, Donald and Levis, Mark 2009. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may Influence relapse risk. Blood -New York- 114 (22) , p. 326.

Russell, N. H., Hills, Robert Kerrin, Hunter, A. E., Milligan, D., Kell, W. J., Wheatley, K., McMullin, M. F., Yin, J. A. L., Bowen, D. T. and Burnett, Alan Kenneth 2009. Low dose Ara-C versus low dose Ara-C and arsenic trioxide: The UK NCRI AML16 "Pick a Winner" comparison [Abstract]. Blood 114 (22) , p. 201.

Russell, Nigel H., Howman, Andrew J., Wheatley, Keith, Hills, Robert Kerrin, Craddock, Charles, Kjeldsen, Lars, Yin, John A. L. and Burnett, Alan Kenneth 2009. Outcome of reduced intensity allografts in patients aged over 45 years with Acute Myeloid Leukaemia: initial results of the MRC AML15 trial. Blood -New York- 114 (22) , p. 217.

Grimwade, David, Jovanovic, Jelena V., Hills, Robert Kerrin, Nugent, Elizabeth A., Patel, Yashma, Flora, Rajinder, Diverio, Daniela, Jones, Katy, Aslett, Hannah, Batson, Elaine, Rennie, Kristian, Angell, Roger, Clark, Richard E., Solomon, Ellen, Lo-Coco, Francesca, Wheatley, Keith and Burnett, Alan Kenneth 2009. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology 27 (22) , pp. 3650-3658. 10.1200/JCO.2008.20.1533

McLornan, P., McMullin, M. F., Mills, Kenneth Ian, Hills, Robert Kerrin, Gilkes, Amanda F., Burnett, Alan Kenneth, Johnston, P. and Longley, D. B. 2009. The prognostic role of C-Flip in AML [Abstract]. Haematologica 94 (S2) , p. 108.

Burnett, Alan Kenneth, Milligan, D., Goldstone, A., Prentice, A., McMullin, M. F., Dennis, M., Sellwood, E., Pallis, M, Russell, N., Hills, Robert Kerrin and Wheatley, K. 2009. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology 145 (3) , pp. 318-332. 10.1111/j.1365-2141.2009.07604.x

Hewamana, Saman, Lin, Thet Thet, Rowntree, Clare, Karunanithi, Kamaraj, Pratt, Guy, Hills, Robert Kerrin, Fegan, Christopher Daniel, Brennan, Paul and Pepper, Christopher John 2009. Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. Journal of Clinical Oncology 27 (5) , pp. 763-769. 10.1200/JCO.2008.19.1114

Daniels, Jane, Gray, Richard, Hills, Robert Kerrin, Latthe, Pallavi, Buckley, Laura, Gupta, Janesh, Selman, Tara, Adey, Elizabeth, Xiong, Tengbin, Champaneria, Rita, Lilford, Richard and Khan, Khalid S. 2009. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA - The Journal of the American Medical Association 302 (9) , pp. 955-961. 10.1001/jama.2009.1268

Fitzgibbon, J., Gale, R., Hills, Robert Kerrin, Virappane, P., Burnett, Alan Kenneth, Lister, T. A. and Linch, D. 2009. In Reply [to 'Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia' by Bruno C. Medeiros] [Letter]. Journal of Clinical Oncology 27 (3) , pp. 474-476. 10.1200/JCO.2008.19.4894

Grimwade, D., Jovanovic, J. V., Hills, Robert Kerrin, Solomon, E., Lo-Coco, F., Wheatley, K. and Burnett, Alan Kenneth 2009. Reply to S. Nagai et al [Letter]. Journal of Clinical Oncology 28 (4) , e63-e64. 10.1200/JCO.2009.25.0522

Daniels, J., Gray, J., Pattison, H., Edwards, E., Milner, P., Spicer, L., King, E., Hills, Robert Kerrin, Gray, R., Buckley, L., Magill, L., Elliman, N., Kaambwa, B., Bryan, S., Howard, R., Thompson, P. and Khan, K. S. 2009. Rapid testing for group B streptococcus during labour: a test accuracy study with evaluation of acceptability and cost-effectiveness. Health Technology Assessment 13 (42) , pp. 1-178. 10.3310/hta13420
file

Hills, Robert Kerrin, Gray, Richard and Wheatley, Keith 2009. Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. Journal of Evidence-Based Medicine 2 (3) , pp. 196-204. 10.1111/j.1756-5391.2009.01023.x

Pepper, Christopher John, Lin, Thet Thet, Pratt, Guy, Hewamana, Saman, Brennan, Paul, Hiller, Louise, Hills, Robert Kerrin, Ward, Rachel, Starczynski, Jane, Austen, Belinda, Hooper, Laura, Stankovic, Tatjana and Fegan, Christopher Daniel 2008. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112 (9) , pp. 3807-3817. 10.1182/blood-2008-05-157131

Mansour, M. R., Gale, R., Khwaja, A., Pule, M, Hills, Robert Kerrin, Burnett, Alan Kenneth and Linch, D. 2008. CSL-TREX: A novel alternatively spliced isoform of CSL (RBPJ-K) predominates over the full-length isoform in many patients with acute myeloid leukaemia can activate notch signalling and is associated with improved outcome [Abstract]. Blood 112 (11) , p. 1155.

Virappane, P., Gale, R., Hills, Robert Kerrin, Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., Burnett, Alan Kenneth, Linch, D., Bonnet, D., Lister, T. A. and Fitzgibbon, J. 2008. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology 26 (33) , pp. 5429-5435. 10.1200/JCO.2008.16.0333

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald, Kell, William J., Wheatley, Keith, Virchis, Andres E. and Russell, Nigel H. 2008. Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract]. Blood -New York- 112 (11) , pp. 1017-1018.

Hills, Robert Kerrin, O'Brien, S., Karsten, V., Burnett, Alan Kenneth and Giles, F. 2008. A retrospective comparison of matched elderly patients treated with Laromustine (Cloretazine (R)) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial [Abstract]. Blood 112 (11) , p. 1017.

Gale, Rosemary, Hills, Robert Kerrin, Green, Claire, Patel, Yashma, Gilkes, Amanda F., Lazenby, Michelle, Wheatley, Keith, Linch, David C. and Burnett, Alan Kenneth 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112 (11) , p. 207.

Liu-Yin, John A., Sale, M., Daly, Sarah B., Hills, Robert Kerrin, Wheatley, Keith and Burnett, Alan Kenneth 2008. Predictive value of Minimal Residual Disease (MRD) monitoring by RQ-PCR in WT1 positive patients entered in the UK MRC AML-15 trial. Blood -New York- 112 (11) , pp. 259-260.

Cilloni, D., Renneville, A., Hermitte, F., Hills, Robert Kerrin, Daly, S., Jovanovic, J., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B., van der Velden, V., Rohon, P., Ommen, H., Polak, J., Jansen, J., Preudhomme, C., Saglio, G. and Grimwade, David 2008. Early assessment of minimal residual disease (MRD) by optimized real-time quantitative PCR (RQ-PCR) assay for detection of WTL transcripts provides an independent predictor of disease relapse in Acute Myeloid Leukemia: a European Leukemianet (ELN) Study. Haematologica 93 , p. 169.

Grimwade, D., Jovanovic, J. V., Hills, Robert Kerrin, Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Clark, R. E., Solomon, E., Lo Coco, F., Wheatley, K. and Burnett, Alan Kenneth 2008. Evaluation of prospective real-time quantitative PCR monitoring for minimal residual disease to predict relapse and direct molecularly targeted therapy with arsenic trioxide in acute promyelocytic leukaemia: analysis of 407 patients, including results of the MRC AML15 trial [Abstract]. British Journal of Haematology 141 (S1) , p. 59.

Bowen, D., Groves, M. J., Burnett, Alan Kenneth, Patel, Y., Allen, C., Green, C., Gale, R. E., Hills, Robert Kerrin and Linch, D. C. 2008. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis [Letter]. Leukemia 23 (1) , pp. 203-206. 10.1038/leu.2008.173

Gale, Rosemary E., Green, Claire, Allen, Christopher, Mead, Adam J., Burnett, Alan Kenneth, Hills, Robert Kerrin and Linch, David C. 2008. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111 (5) , pp. 2776-2784. 10.1182/blood-2007-08-109090

Mead, Adam J., Gale, Rosemary E., Hills, Robert Kerrin, Gupta, Manu, Young, Bryan D., Burnett, Alan Kenneth and Linch, David C. 2008. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease [Letter]. Blood 112 (2) , pp. 444-445. 10.1182/blood-2008-02-140392

Hills, Robert Kerrin 2008. Research in cancer. In: Hanna, Louise, Crosby, Tom and Macbeth, Fergus eds. Practical clinical oncology, Cambridge: Cambridge University Press, pp. 55-69.

Guy, Carol, Gilkes, Amanda F., Gale, Rosemary, Linch, David C., Hills, Robert Kerrin and Burnett, Alan Kenneth 2008. The impact of MN1 over-expression on the outcome of younger patients with AML treated with intensive chemotherapy with or without ATRA therapy [Abstract]. Blood -New York- 112 (11) , p. 1023.

Gray, R., Barnwell, J., McConkey, C., Hills, Robert Kerrin, Williams, N. S. and Kerr, D. J. 2007. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (9604) , pp. 2020-2029. 10.1016/S0140-6736(07)61866-2

Bentham, P., Gray, R., Sellwood, E., Hills, Robert Kerrin, Crome, P. and Raftery, J. 2007. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. The Lancet Neurology 7 (1) , pp. 41-49.

Burnett, Alan Kenneth, Hills, Robert Kerrin, Grimwade, David, Goldstone, Anthony H., Hunter, Ann, Milligan, Donald, Prentice, Archie G., Russell, Nigel H. and Wheatley, Keith 2007. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial. Blood -New York- 110 (11) , 181A-181A.

Cilloni, D., Renneville, A., Hermitte, F., Hills, Robert Kerrin, Daly, S., Jovanovic, J., Gottardi, E., Fava, M., Schnittger, S., Izzo, B., Nomdedeu, J., Van der Heijden, A., Van der Velden, V., Rohon, P., Ommen, H., Polak, J., Jansen, J., Preudhomme, C., Saglio, G. and Grimwade, D. 2007. Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): A European leukemia net study [Abstract]. Blood 110 (11) , 167A.

Yin, J. A. L., Daly, S. B., Sale, M. A., Green, S., Tobal, K., Hills, Robert Kerrin and Burnett, Alan Kenneth 2007. Minimal residual disease monitoring by RQ-PCR in core binding factor positive AML allows risk-stratification and predicts relapse: Results of the UK MRC AML-15 trial. Blood 110 (11) , 167A.

Young, A., Gross, L., Wheatley, K. and Hills, Robert Kerrin 2007. Meta-analysis of randomised comparisons between the effects of warfarin and low molecular weight heparin in thromboprophylaxis and mortality in cancer patients [Abstract]. EJC Supplements 5 (4) , p. 142.

Mead, Adam J., Linch, David C., Hills, Robert Kerrin, Wheatley, Keith, Burnett, Alan Kenneth and Gale, Rosemary E. 2007. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110 (4) , pp. 1262-1270. 10.1182/blood-2006-04-015826

Virappane, P., Gale, R. E., Hills, Robert Kerrin, Kakkas, K., Summers, K., Stevens, J., Green, C. L., Allen, C. G., Quentmeier, H., Drexler, H., Burnett, Alan Kenneth, Linch, D. .C, Bonnet, D., Listens, T. A. and Fitzgibbon, J. 2007. Wilms' tumour 1 mutation in normal karyotype aml. Haematologica 92 (S1) , pp. 19-20.

Grimwade, D., Jovanovic, J. .V, Diverio, D., Nugent, E., Ho, A. Y., Mufti, G. J., Harrison, P., Neilson, J., Solomon, E., Hills, Robert Kerrin, Clark, R. E., Lo Coco, F. and Burnett, Alan Kerrin 2007. Use of quantitative PCR approaches to predict relapse and direct molecularly targeted therapy with arsenic trioxide (ATO) in acute promyelocytic leukaemia (APL)[Abstract]. British Journal of Haematology 137 (S1) , p. 39. 10.1111/j.1365-2141.2007.06557.x

Burnett, Alan Kenneth, Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert Kerrin and Wheatley, Keith 2007. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109 (6) , pp. 1114-1124. 10.1002/cncr.22496

Tonks, Alex, Hills, Robert Kerrin, White, Paul Charles, Rosie, B., Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21 (3) , pp. 566-568. 10.1038/sj.leu.2404559

Tonks, Alex, Hills, Robert Kerrin, White, Paul Charles, Rosie, B., Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21 (3) , pp. 566-568. 10.1038/sj.leu.2404559

Kettle, Christine, Hills, Robert Kerrin and Ismail, Khaled M. K. 2007. Continuous versus interrupted sutures for repair of episiotomy or second degree tears. Cochrane Database of Systematic Reviews 17 (4) 10.1002/14651858.CD000947.pub2

Wheatley, K., Hills, Robert Kerrin and Burnett, Alan Kenneth 2006. Problems with up-front randomization in clinical trials. Journal of Clinical Oncology 24 (34) , pp. 5471-5472. 10.1200/JCO.2006.08.3048

Hills, Robert Kerrin, Kell, W. J. and Burnett, Alan Kenneth 2006. Treatment of AML in the elderly: Who is "Fit" for intensive chemotherapy? Blood -New York- 108 (11) , 559A-559A.

Burnett, Alan Kenneth, Kell, William J., Hills, Robert Kerrin, Russe, Nigel H., Yin, John, Hunter, Ann and Culligan, Dominic 2006. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin ts feasible and effective. A pilot study. Blood -New York- 108 (11) , 551A-552A.

Grimwade, David, Jovanovic, J. V., Diverio, D, Nugent, E, Ho, A. Y., Mufti, G. J., Hills, Robert Kerrin, Solomon, E., Clark, R. E., Lo Coco, F. and Burnett, Alan K. 2006. Real-time detection of PML-RARA and RARA-PML fusion transcripts in high risk acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO): Implications for realization of pre-emptive therapy for molecular relapse. Blood -New York- 108 (11) , 149A-150A.

Burnett, Alan Kenneth, Baccarani, M., Johnson, Peter, Yin, John, Sounders, Andrew, Russell, Nigel and Hills, Robert Kerrin 2006. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood -New York- 108 (11) , 130A-130A.

Burnett, Alan Kenneth, Hills, Robert K., Wheatley, Keith, Goldstone, Anthony H., Prentice, Archie G. and Milligan, Donald 2006. A sensitive risk score for directing treatment in younger patients with AML. Blood -New York- 108 (11) , 10A-10A.

Burnett, Alan Kenneth, Kell, William J., Goldstone, Anthony H., Milligan, Donald, Hunter, Ann, Prentice, Archie G., Russell, Nigel H., Gibson, Brenda, Wheatley, Keith and Hills, Robert Kerrin 2006. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood -New York- 108 (11) , 8A-8A.

Hills, Robert Kerrin and Daniels, Jane 2006. Assessing new interventions in women's health. Best Practice & Research Clinical Obstetrics & Gynaecology 20 (5) , pp. 713-728.

Wallace, Louise M., Dunn, Orla M., Alder, Elizabeth M., Inch, Sally, Hills, Robert Kerrin and Law, Susan M. 2006. A randomised-controlled trial in England of a postnatal midwifery intervention on breast-feeding duration. Midwifery 22 (3) , pp. 262-273.

Jordanides, N. E., Keith, W. N., Hills, Robert Kerrin, Wheatley, Keith, Luong, Quang T., Burnett, Alan Kenneth, Holyoake, T. L. and Drummond, M. W. 2006. hTERT expression in AML is heterogeneous and is of likely prognostic significance. British Journal of Haematology 133 (S1) , p. 63. 10.1111/j.1365-2141.2006.06027.x

Rao, Anupama, Hills, Robert Kerrin, Stiller, Charles, Gibson, Brenda E. S., de Graaf, Siebold S. N., Hann, Ian M., O'Marcaigh, Aengus, Wheatley, Keith and Webb, David K. H. 2006. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. British Journal of Haematology 132 (5) , pp. 576-583. 10.1111/j.1365-2141.2005.05906.x

Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., Nomura, Y., Sakai, K., Sugimachi, K., Tominaga, T., Uchino, J., Yoshida, M., Haybittle, J. L., Davies, C., Harvey, V. J., Holdaway, T. M., Kay, R. G., Mason, B. H., Forbes, J. F., Wilcken, N., Gnant, M., Jakesz, R., Ploner, M., Yosef, H. M. A., Focan, C., Lobelle, J. P., Peek, U., Oates, G. D., Powell, J., Durand, M., Mauriac, L., Di Leo, A., Dolci, S., Piccart, M. J., Masood, M. B., Parker, D., Price, J. J., Hupperets, P. S. G. J., Jackson, S., Ragaz, J., Berry, D., Broadwater, G., Cirrincione, C., Muss, H., Norton, L., Weiss, R. B., Abu-Zahra, H. T., Portnoj, S. M., Baum, M, Cuzick, J., Houghton, J., Riley, D., Mansel, Robert Edward, Gordon, N. H., Davis, H. L., Beatrice, A., Mihura, J., Naja, A., Lehingue, Y., Romestaing, P., Dubois, J. B., Delozier, T., Lesec'h, J. M., Rambert, P., Petruzelka, L., Pribylova, O., Owen, J. R., Harbeck, N., Janicke, F., Meisner, G., Meier, P., Howell, A., Ribeiro, G. C., Swindell, R., Burrett, J., Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., Godwin, J., Gray, R., Harwood, C., Hicks, C., Jackson, D., James, S., MacKinnon, E., McGale, P., McHugh, T., Mead, G., Morris, P., Oulds, J., Peto, R., Taylor, C., Wang, Y., Albano, J., de Oliveira, C. F., Gervasio, H., Gordilho, J., Johansen, H., Mouridsen, H. T., Gelman, R. S., Harris, J. R., Henderson, I. C., Shapiro, C. .L, Christiansen, P., Ejlertsen, B., Mouridsen, H. T., Moller, S., Overgaard, M., Carstensen, B., Palshof, T., Trampisch, H. J., Dalesio, O., de Vries, E. G. E., Rodenhuis, S., van Tinteren, H., Comis, R. L., Davidson, N. E., Gray, R., Robert, N., Sledge, G., Tormey, D. C., Wood, W., Cameron, D., Chetty, U., Forrest, P., Jack, W., Rossbach, J., Klijn, J. G. M., Treurniet-Donker, A. D., van Putten, W. L. J., Costa, A., Veronesi, U., Bartelink, H., Duchateau, L, Legrand, C., Sylvester, R., Catalano, R., Creech, R. H., Bonneterre, J., Fargeot, P., Fumoleau, P., Kerbrat, P., Namer, M., Jonat, W., Kaufman, M., Schumacher, M., von Minckwitz, G., Bastert, G., Rauschecker, H., Sauer, R., Sauerbrei, W., Schauer, A., Schumacher, M., de Schyrver, A., Vakaet, L., Belfiglio, M., Nicolucci, A., Pellegrini, F., Sacco, M., Valentini, M., McArdle, C. S., Smith, D. C., Galligioni, E., Boccardo, F., Rubagotti, A., Dent, D. M., Gudgeon, C. A., Hacking, A., Erazo, A., Medina, J. Y., Izuo, M., Morishita, Y., Takei, H., Fentiman, I.S., Hayward, J. L., Rubens, R. D., Skilton, D., Scheurlen, H, Kaufmann, M., von Fournier, D., Dafni, U., Fountzilas, G., Klefstrom, P., Blomqvist, C, Saarto, T., Magreiter, R., Asselain, B., Salmon, R. J., Vilcoq, J. R., Arriagada, R., Hill, C., Laplanche, A, Le, M. G., Spielmann, M., Bruzzi, P., Montanaro, E., Rosso, R., Sertoli, M. R., Venturini, M., Amadori, D., Benraadt, J., Kooi, M., van de Velde, A. O., van Dongen, J. A., Vermorken, J. B., Castiglione, M., Cavalli, F., Coates, A., Collins, J, Forbes, J., Gelber, R. D., Goldhirsch, A., Lindtner, J., Price, K. N., Rudenstam, C..M., Senn, H. J., Bliss, J. M., Chilvers, C. E. D., Coombes, R. C., Hall, E., Marty, M., Borovik, R, Brufman, G., Hayat, H., Robinson, E., Wigler, N., Bonadonna, G., Camerini, T., De Palo, G., Del Vecchio, M., Formelli, F., Valagussa, P., Martoni, A., Pannuti, F., Cocconi, G., Colozza, A., Camisa, R., Aogi, K., Takashima, S., Abe, O., Ikeda, T., Inokuchi, K., Kikuchi, K., Sawa, K., Sonoo, H., Korzeniowski, S., Skolyszewski, J., Ogawa, M., Yamashita, J., Bonte, J., Christiaens, R., Paridaens, R., Van den Bogaert, W., Martin, P., Romain, S, Hakes, T., Hudis, C. A., Norton, L., Wittes, R., Giokas, G., Kondylis, D., Lissaios, B., de la Huerta, R., Sainz, M. G., Altemus, R., Cowan, K., Danforth, D., Lichter, A., Lippman, M., O'Shaughnessy, J., Pierce, L. J., Steinberg, S., Venzon, D., Zujewski, J. A., Paradiso, A., De Lena, M., Schittulli, F., Myles, J. D., Pater, J. L., Pritchard, K. I., Whelan, T., Nomura, Y., Anderson, S., Bass, G., Brown, A., Bryant, J., Costantino, J., Dignam, J., Fisher, B., Redmond, C., Wieand, S., Wolmark, N., Baum, M., Jackson, I. M., Palmer, M. K., Ingle, J. N., Suman, V. J., Bengtsson, N. O., Jonsson, H., Larsson, L. G., Lythgoe, J. P., Swindell, R., Kissin, M., Erikstein, B., Hannisdal, E, Jacobsen, A. B., Varhaug, J. E., Erikstein, B., Gundersen, S., Hauer-Jensen, M., Host, H., Jacobsen, A. B., Nissen-Meyer, R., Blamey, R. W., Mitchell, A. K., Morgan, D. A. L., Robertson, J. F. R., Di Palma, M., Mathe, G., Misset, J. .L, Clark, R. M., Levine, M., Pritchard, K. .I, Whelan, T., Morimoto, K., Sawa, K., Takatsuka, Y., Crossley, E., Harris, A., Talbot, D., Taylor, M., Cocconi, G., di Blasio, B., Ivanov, V., Semiglazov, V., Brockschmidt, J., Cooper, M. R., Ueo, H., Falkson, C. I., A'Hern, R., Ashley, S., Powles, T. J., Smith, I. E., Yarnold, J. R., Gazet, J. C., Cocoran, N., Deshpande, N., de Martino, L., Douglas, P., Hacking, A., Host, H., Lindtner, A., Notter, G., Bryant, A. J. S., Ewing, G. H., Firth, L. A., Krushen-Kosloski, J. L., Nissen-Meyer, R., Foster, L, George, W. D., Stewart, H. J., Stroner, P., Malmstrom, P., Moller, T. R., Ryden, S., Tengrup, I., Tennvall-Nittby, L., Carstenssen, J., Dufmats, M., Hatschek, T., Nordenskjold, B., Soderberg, M., Carpenter, J. T., Albain, K., Crowley, J., Green, S., Martino, S., Osborne, C. K., Ravdin, P. M., Glas, U., Johansson, U., Rutqvist, L. E., Singnomklao, T., Wallgren, A., Castiglione, M., Goldhirsch, A., Maibach, R., Senn, H. J., Thurlimann, B., Brenner, H., Hercbergs, A., Yoshimoto, M., DeBoer, G., Paterson, A. H. G., Pritchard, K. I., Meakin, J. W., Panzarella, T., Pritchard, K. .I, Shan, Y., Shao, Y. F., Wang, X., Zhao, D. B., Bahi, J., Reid, M., Spittle, M., Deutsch, G. P., Senanayake, F., Kwong, D. L.W, Bianco, A. R., Carlomagno, C., De Laurentiis, M., De Placido, S., Buzdar, A. U., Smith, T., Bergh, J., Holmberg, L., Liljegren, G, Nilsson, J., Seifert, M., Sevelda, P, Zielinsky, C. C., Buchanan, R. B., Cross, M., Royle, G. T., Dunn, J. A., Hills, Robert Kerrin, Lee, M., Morrison, J. M., Spooner, D., Litton, A., Chlebowski, R. T. and Caffier, H. 2005. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet 366 (9503) , pp. 2087-2106.

Gibson, B. E. S., Wheatley, K., Hann, I. M., Stevens, R. F., Webb, D., Hills, Robert Kerrin, De Graaf, S. S. N., Harrison, C. J., United Kingdom Childhood Leukaemia Working Party, and Dutch Childhood Oncology Group, 2005. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19 (12) , pp. 2130-2138. 10.1038/sj.leu.2403924

Wheatley, K., Brookes, C. L, Hills, Robert Kerrin, Goldstone, A. H., Milligan, D. W., Prentice, A. G., Moorman, A. V. and Burnett, Alan Kenneth 2005. Prognostic factors in older AML patients receiving intensive and non-intensive therapy: Analysis of the UK AML11 and AML14 trials [Abstract]. Blood 106 (11) , 199A.

Mead, Adam, Linch, David, Hills, Robert Kerrin, Wheatley, Keith, Burnett, Alan Kenneth and Gale, Rosemary 2005. Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications [Abstract]. Blood 106 (11) , 334.

Gale, Rosemary E., Hills, Robert Kerrin, Kottaridis, Panagiotis D., Srirangan, Sivatharsini, Wheatley, Keith, Burnett, Alan Kenneth and Linch, David C. 2005. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106 (10) , pp. 3658-65. 10.1182/blood-2005-03-1323

Wheatley, Keith, Gross, L. E., Hills, Robert Kerrin and Young, A. M. 2005. Meta-analyses of randomised controlled trials (RCT) of warfarin and low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) and death in cancer patients. Blood -New York- 106 (11) , 267A-267A.

Bowen, David T., Frew, Marion E., Hills, Robert Kerrin, Gale, Rosemary E., Wheatley, Keith, Groves, Michael J., Langabeer, Stephen E., Kottaridis, Panagiotis D., Moorman, Anthony V., Burnett, Alan Kenneth and Linch, David C. 2005. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106 (6) , pp. 2113-2119. 10.1182/blood-2005-03-0867

al-Jurf, Mahmoud, Aranha, Francisco, Annasetti, Claudio, Apperley, Jane F., Baynes, Roy, Bensinger, William I., Blaise, Didier, Chaudhary, M. Ashraf, Clarke, Mike, Cornelissen, Jan J, Couban, Stephen, Cutler, Corey, Djulbegovic, Benjamin, Gyger, Martin, Gratwohl, Alois, Heldal, Dag and Hills, Robert Kerrin 2005. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Journal of Clinical Oncology 23 (22) , pp. 5074-5087. 10.1200/JCO.2005.09.020

Hayden, R. E., Luong, Q. T., Hills, Robert Kerrin, Wheatley, K., Khanim, K. L., Steeg, P. S., Drayson, M. T. and Bunce, C. M. 2005. NM23-H1 acts as a potent survival factor against primary AML cells and normal blast cells [Abstract]. Experimental Hematology 33 (7/S1) , p. 40.

Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., Nomura, Y., Sakai, K., Sugimachi, K., Tominaga, T., Uchino, J., Yoshida, M., Haybittle, J. L., Davies, C., Harvey, V. J., Holdaway, T. M., Kay, R. G., Mason, B. H., Forbes, J. F., Wilcken, N., Gnant, M., Jakesz, R., Ploner, M., Yosef, H. M. A., Focan, C., Lobelle, J. P., Peek, U., Oates, G. D., Powell, J., Durand, M., Mauriac, L., Di Leo, A., Dolci, S., Piccart, M. J., Masood, M. B., Parker, D, Price, J. J., Hupperets, P. S. G. J., Jackson, S., Ragaz, J., Berry, D., Broadwater, G, Cirrincione, C., Muss, H., Norton, L., Weiss, R. B., Abu-Zahra, H. T., Portnoj, S. M., Baum, M., Cuzick, J., Houghton, J., Riley, D., Gordon, N. H., Davis, H. L., Beatrice, A., Mihura, J., Naja, A., Lehingue, Y., Romestaing, P., Dubois, J. B., Delozier, T., Mace-Lesec'h, J., Rambert, P., Andrysek, O., Barkmanova, J., Owen, J. R., Meier, P., Howell, A., Ribeiro, G. C., Swindell, R., Alison, R., Boreham, J., Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., Godwin, J., Gray, R., Harwood, C., Hicks, C., James, S., MacKinnon, E., McGale, P., McHugh, T., Mead, G., Peto, R., Wang, Y., Albano, J., de Oliveira, C. F., Gervasio, H., Gordilho, J., Johansen, H., Mouridsen, H. T., Gelman, R. S., Harris, J. R., Henderson, I. C., Shapiro, C. L., Andersen, K. W., Axelsson, C. K., Blichert-Toft, M., Moller, S., Mouridsen, H. T., Overgaard, J., Overgaard, M., Rose, C., Cartensen, B., Palshof, T., Trampisch, H. J., Dalesio, O., de Vries, E. G. E., Rodenhuis, S., van Tinteren, H., Comis, R. L., Davidson, N. E., Gray, R., Robert, N., Sledge, G., Tormey, D. C., Wood, W., Cameron, D., Chetty, U., Forrest, P., Jack, W, Rossbach, J., Klijn, J. G. M., Treurniet-Donker, A. D., van Putten, W. L. J., Costa, A., Veronesi, U., Bartelink, H., Duchateau, L., Legrand, C., Sylvester, R., van der Hage, J. A., van de Velde, C. J. H., Cunningham, M. P., Catalano, R., Creech, R. H., Bonneterre, J., Fargeot, P., Fumoleau, P., Kerbrat, P., Namer, M., Jonat, W., Kaufmann, M., Schumacher, M., von Minckwitz, G., Bastert, G., Rauschecker, H., Sauer, R., Sauerbrei, W., Schauer, A., Schumacher, M., de Schryver, A., Vakaet, L., Belfiglio, M., Nicolucci, A., Pellegrini, F., Sacco, M., Valentini, M., McArdle, C. S., Smith, D. C., Galligioni, E., Boccardo, F., Rubagotti, A., Dent, D. M., Gudgeon, C. A., Hacking, A., Erazo, A., Medina, J. Y., Izuo, M., Morishita, Y., Takei, H., Fentiman, I. S., Hayward, J. L., Rubens, R. D., Skilton, D., Graeff, H., Janicke, F., Meisner, C., Scheurlen, H., Kaufmann, M., von Fournier, D., Dafni, U., Fountzilas, G, Klefstrom, P., Blomqvist, C., Saarto, T., Margreiter, R., Asselain, B., Salmon, R. J., Vilcoq, J. R., Arriagada, R., Hill, C., Laplanche, A., Le, M. G., Spielmann, M., Bruzzi, P., Montanaro, E., Rosso, R., Sertoli, M. R., Venturini, M., Amadori, D., Benraadt, J., Kooi, M., van de Velde, A. O., van Dongen, J. A., Vermorken, J. B., Castiglione, M., Cavalli, F., Coates, A., Collins, J., Forbes, J., Gelber, R. D., Goldhirsch, A, Lindtner, J., Price, K. N., Rudenstam, C. M., Senn, H. J., Bliss, J. M., Chilvers, C. E. D., Coombes, R. C., Hall, E., Marty, M., Borovik, R., Brufman, G., Hayat, H., Robinson, E., Wigler, N., Bonadonna, G., Camerini, T., De Palo, G., Del Vecchio, M., Formelli, F., Valagussa, P., Martoni, A, Pannuti, F., Cocconi, G., Colozza, A., Camisa, R., Aogi, K., Takashima, S., Abe, O., Ikeda, T., Inokuchi, K., Kikuchi, K., Sawa, K., Sonoo, H., Korzeniowski, S., Skolyszewski, J., Ogawa, M., Yamashita, J., Bonte, J., Christiaens, R., Paridaens, R., Van den Boegart, W., Martin, P., Romain, S., Hakes, T., Hudis, C. A., Norton, L., Wittes, R., Giokas, G., Kondylis, D., Lissaios, B., de la Huerta, R., Sainz, M. G., Altemus, R., Cowan, K., Danforth, D., Lichter, A., Lippman, M., O'Shaughnessy, J., Pierce, L. J., Steinberg, S., Venzon, D., Zujewski, J., Paradiso, A., De Lena, M., Schittulli, F., Myles, J. D., Pater, J. L., Pritchard, K. I., Nomura, Y., Anderson, S., Bass, G., Brown, A., Bryant, J., Costantino, J., Dignam, J., Fisher, B., Redmond, C., Wieand, S., Wolmark, N., Baum, M., Jackson, I. M., Palmer, M. K., Ingle, J. N., Suman, V. J., Bengtsson, N. O., Jonsson, H., Larsson, L. G., Lythgoe, J. P., Swindell, R., Kissin, M., Erikstein, B., Hannisdal, E, Jacobsen, A. B., Varhaug, J. E., Erikstein, B., Gundersen, S., Hauer-Jensen, M., Host, H., Jacobsen, A. B., Nissen-Meyer, R., Blamey, R. W., Mitchell, A. K., Morgan, D. A. L., Robertson, J. F. R., Di Palma, M., Mathe, G., Misset, J. L., Clark, R. M., Levine, M., Morimoto, K, Sawa, K., Takatsuka, Y., Crossley, E., Harris, A., Talbot, D., Taylor, M., Cocconi, G., di Blasio, B., Ivanov, V., Semiglazov, V., Brockschmidt, J., Cooper, M. R., Ueo, H., Falkson, C. I., A'Hern, R., Ashley, S., Powles, T. J., Smith, I. E., Yarnold, J. R., Gazet, J.C., Cocoran, N., Deshpande, N., di Martino, L., Douglas, P., Hacking, A., Host, H., Lindtner, A., Notter, G, Bryant, A. J. S., Ewing, G. H., Firth, L. A., Krushen-Kosloski, J. L., Nissen-Meyer, R., Foster, L., George, W. D., Stewart, H. J., Stroner, P., Malmstrom, P., Moller, T. R., Ryden, S., Tengrup, I., Tennvall-Nittby, L., Carstenssen, J., Dufmats, M., Hatschek, T., Nordenskjold, B., Soderberg, M., Carpenter, J. T., Albain, K., Crowley, J., Green, S., Martino, S, Osborne, C. K., Ravdin, P. M., Glas, U., Johansson, U., Rutqvist, L. E., Singnomklao, T., Wallgren, A., Castiglione, M., Goldhirsch, A., Maibach, R., Senn, H. J., Thurlimann, B, Brenner, H., Hercbergs, A., Yoshimoto, M, DeBoer, G., Paterson, A. H. G., Pritchard, K. I., Meakin, J. W., Panzarella, T., Pritchard, K. I., Shan, Y., Shao, Y. F., Wang, X., Zhao, D. B., Boreham, J., Chen, Z. M., Pan, H. C., Peto, R., Bahi, J., Reid, M., Spittle, M., Deutsch, G. P., Senanayake, F., Kwong, D. L. W., Bianco, A. R., Carlomagno, C., De Laurentiis, M., De Placido, S., Buzdar, A. U., Smith, T., Bergh, J., Holmberg, L., Liljegren, G., Nilsson, J., Seifert, M., Sevelda, P., Zielinsky, C. C., Buchanan, R. B., Cross, M., Royle, G. T., Dunn, J. A., Hills, Robert Kerrin, Lee, M., Morrison, J. M., Spooner, D., Litton, A., Chlebowski, R. T. and Caffier, H. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (9472) , pp. 1687-1717.

Latthe, P. M., Braunholtz, D. A., Hills, Robert Kerrin, Khan, K. S. and Lilford, R. 2005. Measurement of beliefs about effectiveness of laparoscopic uterosacral nerve ablation. BJOG-An International Journal of Obstetrics and Gynaecology 112 (2) , pp. 243-246. 10.1111/j.1471-0528.2004.00304.x

Gale, Rosmary E., Hills, Robert Kerrin, Pizzey, Arnold R., Kottaridis, Panagiotis D., Swirsky, David, Gilkes, Amanda F., Nugent, Elizabeth, Mills, Kenneth I., Wheatley, Keith, Solomon, Ellen, Burnett, Alan Kenneth, Linch, David C. and Grimwade, David 2005. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106 (12) , pp. 3768-3776. 10.1182/blood-2005-04-1746

Allan, James M., Smith, Alexandra G., Wheatley, Keith, Hills, Robert Kerrin, Travis, Lois B., Hill, Deirdre A., Swirsky, David M., Morgan, Gareth J. and Wild, Christopher P. 2004. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104 (13) , pp. 3872-3877. 10.1182/blood-2004-06-2161

Allan, James M., Smith, Alexandra G., Wheatley, Keith, Hills, Robert Kerrin, Travis, Lois B., Hill, Deidre A., Swirsky, David M., Morgan, Gareth J. and Wild, Christopher P. 2004. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104 (13) , pp. 3872-3877. 10.1182/blood-2004-06-2161

Burnett, Alan Kenneth, Hills, Robert Kerrin, Goldstone, A. H., Milligan, D., Prentice, A. G., Hann, I., Webb, D., Gibson, B. and Wheatley, K. 2004. The impact of transplant in AML in 2nd CR: A prospective study of 741 in the MRC AML 10 and 12 Trials [Abstract]. Blood 104 (11) , 179A.

Burnett, Alan Kenneth, Milligan, Donald, Hills, Robert Kerrin, Goldstone, Anthony H., Prentice, Archie G., Wheatley, Keith, Webb, David C. and Gibson, Brenda 2004. Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials [Abstract]. Blood 104 (11) , 1794.

Kumar, A, Soares, H. P., Wells, R. J., Khayat, A., Clarke, M., Hills, Robert Kerrin, Bleyer, A., Reaman, G. and Djulbegovic, B. 2004. Experimental vs control interventions in cancer therapy: Which is better? - The Children's Oncology Group experience. Journal of Clinical Oncology 22 (14) , 523S-523S.

Hills, Robert, Richards, S. M. and Wheatley, Keith 2003. Corner cutting compromises clinical trials: the inherent problems with up-front randomisation and a common standard arm. Leukemia Research 27 (12) , pp. 1071-1073. 10.1016/S0145-2126(03)00126-7

Burnett, Alan Kenneth, Hills, Robert Kerrin and Wheatley, Keith 2003. Does centre size influence outcome in the treatment of AML in adult patients under 60 years? The MRC AML trial experience [Abstract]. Blood 102 (11) , 616A-617A.

Burnett, Alan Kenneth, Hills, Robert Kerrin, Goldstone, A. H., Prentice, A., Milligan, D., Pallis, M., Russell, N., Truran, L. N. and Wheatley, K. 2003. Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial. Blood 102 (11) , 614A.

Luong, Quang T., Hills, Robert Kerrin, Drayson, Mark T., Wheatley, Keith, Burnett, Alan Kenneth, Linch, David C. and Bunce, Christopher M. 2003. Expression of Nm23-H1 in AML correlates with white cell count at diagnosis and in vitro acts as a survival factor for primary AMLs cells; evidence of a novel autocrine survival factor in AML. Blood -New York- 102 (11) , 611A-611A.

Harrison, Christine J., Hills, Robert Kerrin, Moorman, Anthony V., Grimwade, David J., Hann, Ian M., Webb, David K. H., Wheatley, Keith, de Graff, Siebold S. N., van den Berg, Eva, Burnett, Alan K. and Gibson, Brenda E. S. 2003. Cytogenetics of childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. Blood -New York- 102 (11) , 98A-98A.

Jan, S, Hills, Robert Kerrin and Gray, R 2003. PROSPER: A uniquely flexible randomised controlled trial in rectal prolapse repair. Controlled Clinical Trials 24 (S3) , 107S.

Stowe, R. L., Wheatley, K., Clarke, C. E., Ives, N. J., Hills, Robert Kerrin, Williams, A. C., Daniels, J. P. and Gray, R. 2003. Surgery for Parkinson's disease: lack of reliable clinical trial evidence. Journal of Neurology, Neurosurgery & Psychiatry 74 (4) , pp. 519-521. 10.1136/jnnp.74.4.519

Kettle, Christine, Hills, Robert Kerrin, Jones, Peter, Darby, Louisa, Gray, Richard and Johanson, Richard 2002. Continuous versus interrupted perineal repair with standard or rapidly absorbed sutures after spontaneous vaginal birth: a randomised controlled trial. The Lancet 359 (9325) , pp. 2217-2223.

Wheatley, Keith, Stowe, Rebecca L., Clarke, Carl E., Hills, Robert Kerrin, Williams, Adrian C. and Gray, Richard 2002. Evaluating drug treatments for Parkinson's disease: how good are the trials? British Medical Journal 324 (7352) , pp. 1508-1511.
file

Wheatley, K. and Hills, Robert Kerrin 2001. Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study [Letter]. Leukemia 15 (11) , pp. 1803-1804.

Gray, R., Hills, Robert Kerrin, Stowe, R., Clarke, M., Peto, R., Buyse, M. and Piedbois, P. 2001. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. The Lancet 358 (9290) , pp. 1291-1304. 10.1016/S0140-6736(01)06409-1

Benedict, K. A> and Hills, Robert Kerrin 2001. Magnetoroton scattering by phonons in fractional quantum Hall liquids. Physical Review-B 63 (23) , 235304. 10.1103/PhysRevB.63.235304

Tomlinson, J. W., Holden, N., Hills, Robert Kerrin, Wheatley, K., Clayton, R. N., Bates, A. S., Sheppard, M. C. and Stewart, P. M. 2001. Association between premature mortality and hypopituitarism. Lancet 357 (9254) , pp. 425-431. 10.1016/S0140-6736(00)04006-X

Gray, R. G., Kerr, D. J, McConkey, C. C, Williams, N. S. and Hills, Robert Kerrin 2000. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. The Lancet 355 (9215) , pp. 1588-1596. 10.1016/S0140-6736(00)02214-5

Benedict, K. A., Hills, Robert Kerrin and Mellor, C. J. 1999. Theory of phonon spectroscopy in the fractional quantum Hall regime. Physical Review B 60 (15) , pp. 10984-10996.

This list was generated on Fri Apr 19 05:07:26 2019 BST.